Wechselwirkungen von Neomycin

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Aminoglycosides : Avoid concomitant use with aminoglycosides. (Fachinformation zu Carboplatin, Arzneimittelwechselwirkungen)

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

In vitro mixing of penicillins and aminoglycosides should be avoided during concomitant therapy and the drugs should be administered separately. (Fachinformation zu Dicloxacillin, Arzneimittelwechselwirkungen)

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Reactions including anaphylaxis have been reported [see Adverse Reactions (6.2) ] High levels of FSH indicating primary gonadal failure Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders) [see Indications and Usage (1.1 , 1.2 , 1.3) ] Hypersensitivity reactions to streptomycin or neomycin. (Fachinformation zu Follitropin, Gegenanzeigen)

Because of foscarnet's tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, acyclovir, methotrexate, tacrolimus and intravenous pentamidine (see above) unless the potential benefits outweigh the risks to the patient. (Fachinformation zu Foscarnet, Arzneimittelwechselwirkungen)

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Because the nephrotoxic effects may be additive, the concomitant or sequential use of Pentamidine Isethionate and other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin should be closely monitored and avoided, if possible. (Fachinformation zu Pentamidin, Arzneimittelwechselwirkungen)

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Avoid concomitant use of NEXAVAR with neomycin. (Fachinformation zu Sorafenib, Arzneimittelwechselwirkungen)

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (Fachinformation zu Adefovir, Warnhinweise und Vorsichtsmaßnahmen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Aminoglycosides: Increased potential of nephrotoxicity and ototoxicity. (Fachinformation zu Cefepim, Arzneimittelwechselwirkungen)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (Fachinformation zu Cefotaxim, Arzneimittelwechselwirkungen)

If CEFOTAN® and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated. (Fachinformation zu Cefotetan, Vorsichtsmaßnahmen)

Aminoglycosides: Increased potential of nephrotoxicity. (Fachinformation zu Cefoxitin, Arzneimittelwechselwirkungen)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. (Fachinformation zu Cefprozil, Arzneimittelwechselwirkungen)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (Fachinformation zu Ceftazidim, Arzneimittelwechselwirkungen)

Vancomycin, Amsacrine, Aminoglycosides, and Fluconazole Vancomycin, amsacrine, aminoglycosides, and fluconazole are physically incompatible with ceftriaxone in admixtures [see Dosage and Administration (2.3) ]. (Fachinformation zu Ceftriaxon, Arzneimittelwechselwirkungen)

The safety of cidofovir injection has not been evaluated in patients receiving other known potentially nephrotoxic agents, such as intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents (see DOSAGE AND ADMINISTRATION ). (Fachinformation zu Cidofovir, Warnhinweise)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Therefore, digoxin serum levels should be monitored. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (Fachinformation zu Efavirenz, Lamivudin und Tenofovir, Arzneimittelwechselwirkungen)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (Fachinformation zu Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.5) ] . (Fachinformation zu Emtricitabin, Rilpivirin und Tenofovir, Arzneimittelwechselwirkungen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (Fachinformation zu Mycophenolat, Arzneimittelwechselwirkungen)

Antibiotics Certain antibiotics, particularly neomycin, streptomycin and kanamycin have nondepolarizing neuromuscular blocking action, and therefore, neostigmine dose adjustments may be required to reverse neuromuscular block in patients who have been taking these drugs. (Fachinformation zu Neostigmin, Arzneimittelwechselwirkungen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

In vivo inactivation : When aminoglycosides are administered in conjunction with piperacillin to patients with end-stage renal disease requiring hemodialysis, the concentrations of the aminoglycosides (especially tobramycin) may be significantly reduced and should be monitored. (Fachinformation zu Piperacillin und Tazobactam, Arzneimittelwechselwirkungen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Caution should be exercised when using agents (e.g., aminoglycosides and amphotericin B) that are known to have a deleterious effect on renal function. (Fachinformation zu Sirolimus, Warnhinweise und Vorsichtsmaßnahmen)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (Fachinformation zu Tacrolimus, Warnhinweise und Vorsichtsmaßnahmen)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.2) ]. (Fachinformation zu Tenofovir, Arzneimittelwechselwirkungen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

• Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) (Fachinformation zu Zoledronsäure, Arzneimittelwechselwirkungen)

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (Fachinformation zu Butalbital, Acetylsalicylsäure, Koffein und Codein, Arzneimittelwechselwirkungen)

Drug Interactions Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction. (Fachinformation zu Colistimethat-Natrium, Arzneimittelwechselwirkungen)

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all. (Fachinformation zu Pyridostigmin, Arzneimittelwechselwirkungen)

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)